La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Kazia Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Kazia Therapeutics ha un patrimonio netto totale di A$5.3M e un debito totale di A$359.3K, che porta il suo rapporto debito/patrimonio netto a 6.8%. Le sue attività totali e le sue passività totali sono rispettivamente A$24.4M e A$19.1M.

Informazioni chiave

6.8%

Rapporto debito/patrimonio netto

AU$359.30k

Debito

Indice di copertura degli interessi	n/a
Contanti	AU$3.56m
Patrimonio netto	AU$5.27m
Totale passività	AU$19.12m
Totale attività	AU$24.38m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

Jul 06

Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial

Jun 15

Enrollment gets underway in Kazia's mid-stage lymphoma study

Jun 07

Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer

Dec 10

Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study

Dec 09

Kazia stock +22% on positive paxalisib data in glioblastoma

Nov 18

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { KZIA di A$8.0M ) non coprono le sue passività a breve termine ( A$11.3M ).

Passività a lungo termine: Le attività a breve termine di KZIA ( A$8.0M ) superano le sue passività a lungo termine ( A$7.8M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: KZIA ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di KZIA è aumentato da 0% a 6.8% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: KZIA ha una cash runway sufficiente per 3 mesi in base all'ultimo flusso di cassa libero riportato, ma da allora ha raccolto capitale aggiuntivo.

Previsione Cash Runway: Si prevede che KZIA disponga di liquidità sufficiente per 3 mesi in base alle stime del flusso di cassa libero, ma da allora ha raccolto capitale aggiuntivo.

Kazia Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Kazia Therapeutics Announces Receipt of Nasdaq Minimum Bid Notification

Kazia Announces Receipt of Nasdaq Minimum Bid Notification

Kazia Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Recent updates

Kazia Therapeutics Limited Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients

Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP

New major risk - Share price stability

New major risk - Financial position

New minor risk - Financial data availability

Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Kazia Therapeutics Limited Announces Appointment of Board Members

Kazia Therapeutics Limited Announces Executive Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.981756 million.

Kazia Therapeutics Announces Receipt of Nasdaq Minimum Bid Notification

High number of new and inexperienced directors

Kazia Therapeutics Provides Preliminary Update from Ongoing Phase 2 Study of Paxalisib in Primary Cns Lymphoma

Kazia Therapeutics Limited Announces Clinical Data At ESMO 2023 from Ongoing Phase 1 ESMO Study

Kazia Therapeutics Limited Announces Acceptance of Late-Breaking Abstracts and Oral Presentation of Pnoc022 Clinical Data At 2023 Society for Neuro-Oncology Annual Meeting

Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Appoints John Friend as Managing Director

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.5 million.

Kazia Therapeutics Limited Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy

Kazia Therapeutics Limited Announces Phase II Clinical Study to Investigate Paxalisib in Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma

Kazia Therapeutics Limited Appoints Ms. Ebru Davidson to its Board

Kazia Announces Receipt of Nasdaq Minimum Bid Notification

Kazia Therapeutics Announces the Publication of Pre-Clinical Data for Its Second Pipeline Asset, EVT801 in the Journal Cancer Research Communications

Kazia Therapeutics Limited Announces Publication of Positive Preclinical Data for Evt801

Kazia Therapeutics Limited's Paxalisib Demonstrates Positive Monotherapy Efficacy Signals in Preclinical Models of Melanoma

Kazia Therapeutics Limited Announces Expansion of PNOC Study into Australia

Kazia Therapeutics Limited, Annual General Meeting, Nov 16, 2022

Kazia Therapeutics Limited Presents Promising New Data from an Ongoing Phase I Clinical Trial of Paxalisib in Combination with Radiotherapy

Kazia Therapeutics Limited Provides Progress Update on GBM Agile Pivotal Study

Kazia Therapeutics Limited Launches New Scientific Advisory Board

Kazia Therapeutics Limited Launches New Scientific Advisory Board

United States Food and Drug Administration Awards Rare Pediatric Disease Designation to Kazia Therapeutics Limited's Paxalisib for AT/RT, Rare Form of Childhood Brain Cancer

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

Kazia Therapeutics Limited Provides Progress Update on Paxalisib and EVT801 Clinical Programs

Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Brain Metastases Advances to Expansion Stage in Breast Cancer Brain Metastases Cohort

Kazia Presents Positive Final Data from Phase II Study of Paxalisib in Newly Diagnosed Glioblastoma at ASCO Conference

Kazia to Present Final Data from Paxalisib Phase II Study in Glioblastoma At ASCO

Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Glioblastoma Achieves Final Completion

Kazia Presents Preclinical Data for Paxalisib At AACR

Kazia Therapeutics Limited Announces Phase II Clinical Study at Weill Cornell Medical Center Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet Enrolls First Patient

Kazia Therapeutics Limited Announces First Patient Enrolls in Phase II Clinical Study Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0395 (Paxalisib) Issued by Thenational Medical Products Administration Under Collaboration with Kazia Therapeutics Limited

Kazia Releases Final Data from P2 Paxalisib Trial

Kazia Therapeutics Limited Provides Progress Update on Paxalisib and Evt801 Clinical Programs

Kazia Therapeutics Limited Announces Manufacturing Patents Granted for Paxalisib in Key Territories

Kazia Therapeutics Limited Launches New Paxalisib Phase II Clinical Trial

Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial

Kazia Therapeutics Limited Announces Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

Enrollment gets underway in Kazia's mid-stage lymphoma study

Kazia Therapeutics Limited announced that it expects to receive AUD 5.2 million in funding from Simcere Pharmaceutical Group Limited

Kazia Licenses Cantrixil, to Oasmia Pharmacetical AB

Kazia Therapeutics Limited Announces GBM AGILE Pivotal Study Commences Recruitment to Paxalisib Arm

Kazia Therapeutics Limited to Collaborate with Pacific Pediatric Neuro-Oncology Consortium for New Paxalisib Combination Study in DIPG

Kazia Therapeutics Limited Announces Top-Line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer

Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study

Kazia Therapeutics Limited Presents Further Paxalisib Data At SNO, Confirming Earlier Positive Safety and Efficacy Signals in Glioblastoma

Kazia stock +22% on positive paxalisib data in glioblastoma

Kazia Therapeutics Limited Executes Agreement to Commence GBM Agile Pivotal Study

Kazia Therapeutics Limited Enters into Collaboration with Dana-Farber Cancer Institute in the United States to Investigate the Use of Kazia’S Investigational New Drug, Paxalisib

Kazia Therapeutics Limited Enter New Collaboration with Dana-Farber Cancer Institute

US FDA Awards Orphan Drug Designation to Paxalisib for Malignant Glioma, Including DIPG

Kazia Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane